GlassScriptPhysician profile
Ramesh V Patel
NPI 1396744033
$4,202.64
in general payments reported to CMS, 2019-2025
36 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $128 · 2021: $830 · 2022: $315 · 2023: $1,757 · 2024: $244 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,418 · Food and Beverage: $975 · Travel and Lodging: $11.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,417.50 |
| Food and Beverage | $974.93 |
| Travel and Lodging | $11.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $1,462.30 | 2023 | Epkinly |
| Seagen INC. | $329.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $286.69 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $232.81 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $206.36 | 2019-2024 | Opdualag, Opdivo |
| Incyte Corporation | $198.12 | 2019-2023 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $129.98 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $127.32 | 2019-2025 | Libtayo |
| Pfizer INC. | $104.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $94.46 | 2019-2024 | |
| Tempus Ai, INC | $87.54 | 2024-2025 | Xt Cdx |
| Taiho Oncology, INC. | $86.33 | 2019-2025 | |
| Janssen Biotech, INC. | $84.11 | 2020-2025 | Erleada, Balversa, Akeega |
| Amgen INC. | $76.97 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Celgene Corporation | $71.74 | 2021-2025 | Reblozyl |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $61.04 | 2021 | |
| Daiichi Sankyo INC. | $60.05 | 2019-2021 | |
| Genentech USA, INC. | $54.19 | 2019-2023 | Polivy |
| Lilly USA, LLC | $44.50 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.08 | 2019-2021 | |
| Exelixis INC. | $42.63 | 2019-2023 | Cabometyx |
| Abbvie INC. | $40.85 | 2021-2025 | |
| Genzyme Corporation | $38.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.08 | 2019 | |
| Astellas Pharma US INC | $30.19 | 2019-2022 | |
| Gilead Sciences, INC. | $28.77 | 2021-2024 | |
| Coherus Oncology, INC. | $20.03 | 2021 | |
| Beone Medicines USA, INC. | $19.19 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $18.94 | 2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $16.02 | 2023 | Fotivda |
| Stemline Therapeutics INC. | $16.01 | 2025 | Orserdu |
| Puma Biotechnology, INC. | $15.64 | 2025 | |
| Smith+Nephew, INC. | $12.66 | 2021 | |
| Beigene USA, INC. | $12.13 | 2022 | |
| Karyopharm Therapeutics INC. | $11.11 | 2020 | |
| Clovis Oncology, INC. | $3.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.